HealthTree Logo
search more_vert
close
person Sign In / Create Account
Lenalidomide Can Delay Bone and Organ Damage for Smoldering Myeloma Patients
Posted: Nov 01, 2019
Lenalidomide Can Delay Bone and Organ Damage for Smoldering Myeloma Patients image

In the largest ever study of smoldering myeloma patients from 13 major myeloma facilities, lenalidomide was found to delay disease progression, and helped prevent bone damage and end organ damage. The study was run by the Eastern Cooperative Oncology Group and funded by the National Cancer Institute.

 
"Curative" treatment strategies are also being evaluated for high risk smoldering myeloma patients. Such a study is the ECOG-ACRIN study, comparing daratumumab, lenalidomide, and dexamethasone (with the goal of a cure) vs. lenalidomide plus dexamethasone (with the goal of prevention). The future results from this study can be compared to this current study and will provide clarity on the best long-term strategy for high risk smoldering myeloma. While we are waiting on those results, lead study author Vincent Rajkumar, MD of the Mayo Clinic said:

 

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can contribute to cures by joining HealthTree Cure Hub and joining clinical research. Founder and CEO of HealthTree Foundation. 

Get the latest thought leadership on Large Granular Lymphocytic Leukemia delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Large Granular Lymphocytic Leukemia Newsletter" for Large Granular Lymphocytic Leukemia news, life with Large Granular Lymphocytic Leukemia stories, Large Granular Lymphocytic Leukemia clinical trials, Large Granular Lymphocytic Leukemia 101 articles and events with Large Granular Lymphocytic Leukemia experts.